ESC 365 - Beta-blocker duration and long-term cardiovascular risk after myocardial infarction with reduced ejection fraction

ESC2025 Premium Access

Beta-blocker duration and long-term cardiovascular risk after myocardial infarction with reduced ejection fraction

Session: Post-myocardial infarction management

Topic: Beta-Blockers

Speaker: Doctor S. Fang (Bristol, GB)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Si Fang

University of Bristol, Bristol (United Kingdom of Great Britain & Northern Ireland)

0 follower

6 more presentations in this session

Beta-blockers improved cardiovascular outcome in AMI patients with severe heart failure: a multi-center real-world study

Speaker: Doctor R. Guo (Tianjin, CN)

Impact of beta-blocker prescription at discharge on long-term clinical outcomes in ST-elevation myocardial infarction patients with mid-range left ventricular ejection fraction (40% to 49%)

Speaker: Professor S. Park (Seoul, KR)

Antithrombotic therapy in patients with takotsubo cardiomyopathy: is heparin associated with lower mortality? - a nationwide cohort analysis

Speaker: Doctor S. Hijikata (Tokyo, JP)

Proton pump inhibitors in myocardial infarction: safety paradox in Type 1 vs. Type 2---a multicenter retrospective cohort study

Speaker: Doctor J. Ren (Tianjin, CN)

Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial

Speaker: Professor M. Shechter (Ramat Gan, IL)

Access the full session

Post-myocardial infarction management

Speakers: Doctor S. Fang, Doctor R. Guo, Professor S. Park, Doctor S. Hijikata, Doctor J. Ren...

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources